---
schema_version: "secwatch.filing_event.v1"
accession: "0001055726-25-000013"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T12:52:39.661126+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inovio reports FY2024 net loss $107.3M; on track for INO-3107 BLA submission mid-2025

## Summary
- Net loss $19.4M Q4 ($0.65/share) and $107.3M FY ($3.95/share), narrower than 2023's $135.1M.
- Cash, equivalents & investments $94.1M at Dec 31, 2024, down from $145.3M at Dec 31, 2023.
- BLA for INO-3107 (RRP) on track for rolling submission mid-2025; device verification testing complete H1 2025.
- DMAb interim data: 100% of participants (24/24) maintained antibody levels at week 72; no anti-drug antibodies.
- Raised >$72M from ATM and two equity offerings in 2024; cash runway into Q1 2026.

## SEC filing metadata
- accession: 0001055726-25-000013
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000013/0001055726-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000013/ino-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001055726-25-000013
- JSON: https://secwatch.observer/filing/0001055726-25-000013.json
- Plain text: https://secwatch.observer/filing/0001055726-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.